Jennifer Woo

Aridis Pharmaceuticals, Inc.

Poster(s):

• (507) PHASE 1/2a RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY: SAFETY, PK, AND EFFICACY OUTCOME MEASURES OF INHALED GALLIUM CITRATE (AR-501) IN CYSTIC FIBROSIS PATIENTS
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET